Zydus Cadila receives final USFDA approval for Carbidopa Tablets
Cadila Healthcare, on Thursday, announced receiving final approval from the USFDA for Carbidopa tablets.
The Carbidopa Tablets, 25 mg can be used in a combination levodopa/carbidopa product to treat symptoms of Parkinson's disease or Parkinson-like symptoms like shakiness, stiffness, difficulty moving, etc.
The drug will be manufactured at its manufacturing facility in SEZ, Ahmedabad. The group now has over 190 approvals and has so far filed over 320 ANDAs, since the commencement of the filing process in FY2003-04.
Cadila’s board meeting is scheduled for May 25, 2018 to approve the audited financial results and to recommend dividend for the financial year ended on March 31, 2018.
Zydus Cadila is a global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies.
At 11:00 hours, Cadila Healthcare was trading at Rs. 397.50 per share, down Rs. 2.85 or 0.71 per cent on NSE. The stock opened at Rs. 403 and touched an intra-day high of Rs. 405.80. The scrip has a 52-week high of Rs. 560 and a 52-week low of Rs. 362 per share on NSE. The stock already attracted a volume of 2,47,034 shares on NSE.